Unique ID issued by UMIN | UMIN000017576 |
---|---|
Receipt number | R000020365 |
Scientific Title | Randomized pilot study of optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with mFOLFOX6: HGCSG0703 |
Date of disclosure of the study information | 2015/05/14 |
Last modified on | 2015/05/14 23:43:01 |
Randomized pilot study of optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with mFOLFOX6: HGCSG0703
Randomized pilot study of optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with mFOLFOX6: HGCSG0703
Randomized pilot study of optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with mFOLFOX6: HGCSG0703
Randomized pilot study of optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with mFOLFOX6: HGCSG0703
Japan |
colorectal cancer
Gastroenterology | Hematology and clinical oncology |
Malignancy
NO
To explore the optimal dosing period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with mFOLFOX6
Safety,Efficacy
Exploratory
Phase II
Complete protection from vomiting
Complete protection from nausea
No use of rescue therapy
Tolerability
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
YES
Institution is considered as adjustment factor in dynamic allocation.
NO
Central registration
2
Treatment
Medicine |
3-day indisetron regimen
1-day indisetron regimen
20 | years-old | <= |
80 | years-old | >= |
Male and Female
1. patients with advanced or metastatic colorectal cancer
2. scheduled to receive full dose of mFOLFOX6 as 1st line chemotherapy, with or without targeted agents
3. age 20-80 years old
4. ECOG performance status 0-2
5. written informed consent
1. had any known central nervous system malignancy
2. had any seizure disorder needing anticovulsants
3. had active gastrointestinal ulcers or obstruction
4. had any other organic cause of nausea or vomiting unrelated to chemotherapy
5. were scheduled to undergo radiotherapy
6. were pregnant or nursing women
7. had any history of drug hypersensitivity
40
1st name | |
Middle name | |
Last name | Yoshito Komatsu |
Hokkaido University Hospital
Cancer Center
14-5 Kita-ku, Sapporo, Hokkaido, 060-8648, JPN
81-11-706-5657
ykomatsu@med.hokudai.ac.jp
1st name | |
Middle name | |
Last name | Hiroshi Nakatsumi |
Hokkaido University Hospital
Gastroenterology and Hepatology
14-5 Kita-ku, Sapporo, Hokkaido, 060-8648, JPN
81-11-706-5657
http://www.hgcsg.com/
tsumi1979@gmail.com
Hokkaido Gastrointestinal Cancer Study Group (HGCSG)
Hokkaido Gastrointestinal Cancer Study Group (HGCSG)
Non profit foundation
Japan
none
none
NO
北海道大学病院(北海道)、苫小牧日翔病院(北海道)、苫小牧市立病院(北海道)、札幌北楡病院(北海道)、岩見沢市立総合病院(北海道)、釧路労災病院(北海道)、北見赤十字病院(北海道)、北海道消化器科病院(北海道)
2015 | Year | 05 | Month | 14 | Day |
http://www.hgcsg.com/
Published
http://www.karger.com/Article/FullText/345920
Proportions of patients with complete protection from vomiting were 85.7% (95% confidence interval (CI), 63.7-97.0%) with the 3-day regimen, and 81.0% (95%CI, 58.1-94.6%) with the 1-day regimen. Proportions of patients with complete protection from nausea were 47.6% in each arm (95%CI, 25.7-70.2%). No rescue therapy rates were 66.7% (95%CI, 43.0-85.4%) vs. 57.1% (95%CI, 34.0-78.2%). No severe adverse events were observed in either arm.
Completed
2007 | Year | 12 | Month | 25 | Day |
2008 | Year | 01 | Month | 09 | Day |
2009 | Year | 09 | Month | 04 | Day |
2009 | Year | 09 | Month | 04 | Day |
2009 | Year | 12 | Month | 31 | Day |
2009 | Year | 12 | Month | 31 | Day |
2015 | Year | 05 | Month | 14 | Day |
2015 | Year | 05 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020365
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |